Randomized Study of a Dematerialized Management for Post-Emergency Gynecological Follow-Up (GYNAB)

The GYNAB study aims to compare patient satisfaction and clinical outcomes between dematerialized post-emergency gynecological follow-up using a connected health app and traditional in-person follow-up. Conducted by Drs. Laëtitia CAMPIN and Louis MARCELLIN at Hôpital Cochin, it is sponsored by Assistance Publique - Hôpitaux de Paris. The main objective is to assess patient satisfaction at day 7 on a scale from 0 to 10, considering symptom management, follow-up quality, and task performance. Secondary objectives include comparing satisfaction at day 28, PROM-ED scores for symptom relief, understanding, reassurance, and care planning at days 7 and 28, hospitalization rates, unscheduled consultations, surgical interventions, total hospital time by day 28, and physician satisfaction at 28 days. This randomized trial involves women aged 18-60 needing follow-up for conditions like genital infections, non-complicated ectopic pregnancies, unlocated pregnancy, first trimester metrorrhagia, miscarriages , and severe vomiting before 12 weeks. Inclusion criteria are women aged 18-60 needing specified follow-up. Exclusion criteria are severe clinical intolerance, severe criteria ultrasound findings, non-French speakers, and inability to use digital applications. The intervention group uses a connected health app for data collection and communication, logging symptoms and test results, with medical team notifications for urgent updates. The control group receives traditional in-person follow-up with scheduled consultations and emergency contact information. The study hypothesizes that digital follow-up will improve patient experience, reduce hospital visits, and provide comparable or superior satisfaction and clinical outcomes. The results could promote broader digital health adoption in various medical fields.

Study Overview

• Status: Recruiting
• Conditions: Genital Diseases, Female; Hyperemesis Gravidarum; Ectopic Pregnancy; Abortion, Missed; Uncertain Viability of Pregnancy
• Intervention / Treatment: Device: Participants will receive post-emergency gynecological follow-up at home using a connected health app

Detailed Description

Scientific Justification:

Emergency gynecological consultations are frequent reasons for hospital visits. Some clinical situations require scheduled follow-up to assess the progression of the initial condition through targeted questioning and additional tests such as blood work or pelvic ultrasounds. Digital health platforms, utilizing AI algorithms, have proven valuable in telehealth, appointment scheduling, personalized care, and prevention. These platforms allow secure, asynchronous follow-up, potentially enhancing patient experience and reducing unnecessary hospital visits.

Platform Capabilities: The secure platforms offer features like messaging, video consultations, document scanning, smart medical note-taking, shared medical records, structured questionnaires, and automatic extraction of standardized medical information from consultations, lab results, and other medical documents. Using machine learning, these platforms assist in structuring medical decisions while enabling patients to be active participants in their care.

Evaluation Criteria:

Post-emergency gynecological follow-up is not standardized. Iterative, unscheduled emergency visits can indicate poor care quality, though repeated scheduled visits are sometimes necessary for follow-up and not indicative of poor quality. Patient satisfaction, measured using validated tools like PROMs (Patient-Reported Outcome Measures), is a useful criterion for evaluating care quality. PROMs are increasingly used to assess healthcare quality and patient management, and their digitized, secure, and easily accessible formats allow efficient and standardized data collection.

PROM-ED Questionnaire:

A validated Canadian PROM-ED questionnaire evaluates patient experiences and satisfaction with emergency care, focusing on symptom relief, understanding, reassurance, and care planning. This standardized tool is appropriate for evaluating satisfaction with emergency gynecological care.

Hypothesis:

We hypothesize that dematerialized follow-up using a connected health app will improve patient experience, reduce hospital visits, and lower hospitalization rates compared to traditional follow-up.

Primary Objective:

Compare overall patient satisfaction between dematerialized post-emergency follow-up at home using a health app and traditional in-person follow-up at the hospital seven days after the initial consultation. Satisfaction will be assessed on a scale from 0 to 10, considering symptom management, follow-up quality, and task performance.

Secondary Objectives:

1. Compare satisfaction at 28 days.
2. Evaluate PROM-ED scores for symptom relief, understanding, reassurance, and care planning at days 7 and 28.
3. Assess hospitalization rates by day 28.
4. Assess unscheduled emergency consultations during the study.
5. Assess surgical intervention rates by day 28.
6. Assess total hospital time by day 28.
7. Evaluate physician satisfaction at 28 days.

Design: Randomized superiority trial involving women aged 18-60 consulting for specific gynecological conditions requiring post-emergency follow-up. Inclusion criteria are women aged 18-60 needing specified follow-up. Exclusion criteria are severe clinical intolerance, significant ultrasound findings, non-French speakers, and inability to use digital applications.

Intervention Group: Uses a connected health app for data collection and communication, logging symptoms and test results, with medical team notifications for urgent updates. Patients will record vital signs at nearby pharmacies and log symptoms like pain, bleeding, and vomiting.

Control Group: Receives traditional in-person follow-up with scheduled consultations and emergency contact information.

Data Collection and Randomization: Patients will be randomized into either the intervention or control group. Data will be collected via secure digital platforms, with follow-up evaluations at days 7 and 28. Clinical data will be pseudonymized and securely stored.

Expected Benefits: Improved patient coordination and care efficiency, reduced hospital visits, enhanced access to care, and reduced healthcare costs. The study aims to validate the feasibility and effectiveness of digital health solutions in post-emergency gynecological care. If successful, this could lead to broader adoption of such technologies in various medical fields.

Risks: The study poses minimal risks as it includes patients with stable conditions and ensures continuous monitoring through digital platforms with emergency response capabilities.

Participants: 200 women (100 per group) will be included, based on previous satisfaction scores. Inclusion criteria ensure patient stability and ability to use the digital platform.

Duration: Inclusion will last 24 months, with a 28-day follow-up period for each patient.

Statistical Analysis: Conducted by the statistical team led by Prof. Pierre-Yves Ancel at Université de Paris.

Funding: Private funding by NABLA (40%) and public funding by BPI (60%).

• Study Type: Interventional
• Enrollment (Estimated): 200
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Laetitia CAMPIN, MD; Phone Number: 33 015413680; Email: laetitia.campin@aphp.fr
• Study Contact Backup: Name: Valérie PLENCE; Phone Number: 33 0158411178; Email: valerie.plence-fauroux@aphp.fr

Study Locations

• France
  • Paris, France, 75014
    • Recruiting
    • Hôpital Cochin
    • Contact: Laetitia CAMPAIN, MD, PhD; Phone Number: 33+0158413680; Email: laetitia.campain@aphp.fr
    • Principal Investigator: Laetitia CAMPAIN, MD, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Women aged 18 and 60 years
• No consultation at the gynecological emergency department in the previous month and/or for the same pregnancy.

• Requires post-emergency follow-up for one of the following clinical conditions:

  • Genital Infections (IGH): Acute pelvic pain with or without leucorrhea requiring antibiotic treatment
  • Ectopic Pregnancy (GEU): Non-complicated, not ruptured, no significant effusion on ultrasound, GEU < 4 cm, no cardiac activity if embryo present, stable hemodynamic state, HCG < 5000, compliant patient, no contraindications for Methotrexate
  • Early Pregnancy of Uncertain Viability (GLI): Early stage with a positive bHCG test, no visible gestational sac on ultrasound, no effusion, bHCG < 1500 IU
  • Missed Miscarriage (GAM): Confirmed by an intrauterine gestational sac ≥ 25mm without an embryo or an intrauterine gestational sac with an embryo ≥ 7mm without visible cardiac activity, treated with Misoprostol
  • First Trimester Bleeding (MTRt1): Moderate vaginal bleeding with an ongoing intrauterine pregnancy without hemodynamic instability
  • Hyperemesis Gravidarum (VG): Severe vomiting before 12 weeks of pregnancy without severe criteria necessitating emergency follow-up

Exclusion Criteria:

• Severe clinical intolerance, defined by:

  • Signs of severe sepsis with unstable hemodynamics (TA with SBP < 90 mmHg and FC ≥ 105 bpm)
  • Abdominal defense or contracture
  • Pain not controlled by level 1 analgesics (EVA <7)
  • Severe dehydration defined by a body weight loss of more than 10%
  • Total food intolerance due to vomiting necessitating hospitalization
  • Uncontrolled active hemorrhage

• Significant ultrasound findings:

  • Tubo-ovarian abscess ≥ 3 cm
  • Significant intra-abdominal effusion
• Non-French speaking patients
• Inability to download or use the digital application due to precarious or isolated digital circumstances
• Refusal to sign consent form
• Patients under legal guardianship or court protection (tutelage, curatorship, or guardianship)
• Patients not affiliated with a social security system

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Traditional In-Person Follow-Up; Participants in this arm will receive traditional in-person follow-up at the hospital. They will have scheduled consultations at the emergency department where they will undergo necessary evaluations and receive instructions for follow-up visits. Contact information for urgent needs will also be provided, allowing patients to reach medical services 24/7 if required
Experimental: Dematerialized Follow-Up; Participants in this arm will receive post-emergency gynecological follow-up at home using a connected health app.	Device: Participants will receive post-emergency gynecological follow-up at home using a connected health app; The app will facilitate data collection and communication, including logging of vital signs, symptoms (such as pain, bleeding, and vomiting), and uploading of test results. Medical professionals will review the health data twice daily and provide care instructions through instant messaging. The app will also alert the medical team of any urgent updates or deviations from expected health patterns

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Patient Satisfaction	Measure of overall patient satisfaction with post-emergency gynecological follow-up, assessed on a scale from 0 to 10. This includes symptom management, follow-up quality, and the ability to perform requested tasks.	7 days after initial emergency gynecological consultation

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Patient Satisfaction at 28 Days	Measure of overall patient satisfaction with post-emergency gynecological follow-up, assessed on a scale from 0 to 10 at 28 days. This includes symptom management, follow-up quality, and the ability to perform requested tasks.	28 days after initial emergency gynecological consultation
PROM-ED Score for Symptom Relief	Patient-reported outcome measure for symptom relief, assessed using the PROM-ED questionnaire.	7 days after initial emergency gynecological consultation
PROM-ED Score for Symptom Relief at 28 Days	Patient-reported outcome measure for symptom relief, assessed using the PROM-ED questionnaire.	28 days after initial emergency gynecological consultation
PROM-ED Score for Understanding	Patient-reported outcome measure for symptom relief, assessed using the PROM-ED questionnaire.	7 days after initial emergency gynecological consultation
PROM-ED Score for Understanding at 28 days	Patient-reported outcome measure for symptom relief, assessed using the PROM-ED questionnaire.	28 days after initial emergency gynecological consultation
PROM-ED Score for Reassurance	Patient-reported outcome measure for reassurance and comfort with their care, assessed using the PROM-ED questionnaire.	7 days after initial emergency gynecological consultation
PROM-ED Score for Reassurance at 28 days	Patient-reported outcome measure for reassurance and comfort with their care, assessed using the PROM-ED questionnaire.	28 days after initial emergency gynecological consultation
PROM-ED Score for Care Planning	Patient-reported outcome measure for the effectiveness of care planning, assessed using the PROM-ED questionnaire.	7 days after initial emergency gynecological consultation
PROM-ED Score for Care Planning at 28 days	Patient-reported outcome measure for the effectiveness of care planning, assessed using the PROM-ED questionnaire.	28 days after initial emergency gynecological consultation
Hospitalization rate	The rate of hospital admissions among participants during the study period.	28 days after initial emergency gynecological consultation
Unscheduled Emergency Consultations	Rate of unscheduled emergency consultations during the follow-up period.	28 days after initial emergency gynecological consultation
Surgical Intervention Rate	Rate of surgical interventions among participants during the study period.	28 days after initial emergency gynecological consultation
Total Hospital Time	Total time spent in the hospital by participants during the study period.	28 days after initial emergency gynecological consultation
Physician Satisfaction	Measure of physician satisfaction with patient management, assessed on a scale from 0 to 10.	28 days after initial emergency gynecological consultation

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborators: URC-CIC Paris Descartes Necker Cochin
• Investigators: Study Director: Louis MARCELLIN, MD, PhD, Assistance Publique - Hôpitaux de Paris; Principal Investigator: Laetitia CAMPIN, MD, Assistance Publique - Hôpitaux de Paris

Study record dates

Study Major Dates

• Study Start (Actual): June 30, 2025
• Primary Completion (Estimated): June 30, 2027
• Study Completion (Estimated): July 30, 2027

Study Registration Dates

• First Submitted: September 24, 2024
• First Submitted That Met QC Criteria: September 24, 2024
• First Posted (Actual): September 27, 2024

Study Record Updates

• Last Update Posted (Actual): April 21, 2026
• Last Update Submitted That Met QC Criteria: April 20, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Patient satisfaction; Telehealth; Digital Health; Patient-Reported Outcome Measures (PROMs); Gynecological Emergencies; Post-Emergency Follow-Up; Asynchronous Medical Follow-up
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Signs and Symptoms, Digestive; Pregnancy Complications; Morning Sickness; Vomiting; Abortion, Spontaneous; Pathological Conditions, Signs and Symptoms; Behavior; Signs and Symptoms; Treatment Adherence and Compliance; Health Behavior; Hyperemesis Gravidarum; Genital Diseases, Female; Pregnancy, Ectopic; Abortion, Missed; Patient Satisfaction
• Other Study ID Numbers: APHP230586; 2023-A02336-39 (Registry Identifier: ID-RCB)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No